Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sulforafan alfadex - Evgen Pharma

Next Previous
Drug Profile

Sulforafan alfadex - Evgen Pharma

Alternative Names: Broccoli-sprout-extract; SFX-01; Stabilised sulforaphane; STP-2; Sulforadex; Sulforafan-alpha-cyclodextrin; Sulforaphane; Sulforaphane-alpha-cyclodextrin; Sulphoraphane-alfadex

Latest Information Update: 18 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lalilab
  • Developer Evgen Pharma
  • Class Antihaemorrhagics; Antineoplastics; Behavioural disorder therapies; Chemopreventatives; Phytotherapies
  • Mechanism of Action Androgen receptor antagonists; Hedgehog protein modulators; Histone deacetylase inhibitors; NF E2 related factor 2 stimulants; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III SARS-CoV-2 acute respiratory disease
  • Phase II Breast cancer; Subarachnoid haemorrhage
  • Phase I Pervasive child development disorders
  • Preclinical Glioblastoma; Haematological malignancies; Rhabdomyosarcoma
  • No development reported Cardiovascular disorders; Chronic obstructive pulmonary disease; Leukaemia; Multiple sclerosis

Most Recent Events

  • 18 Jan 2024 Pharmacodynamics data from a preclinical trial in Rhabdomyosarcoma released by Evgen Pharma (Evgen Pharma pipeline January 2024)
  • 16 Jan 2024 Preclinical trials in Rhabdomyosarcoma in United Kingdom (PO) (Evgen Pharma pipeline, January 2024)
  • 31 Mar 2023 Evgen Pharma completes phase I trial in volunteers in wales (EudraCT2022-001601-43)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top